GC023 A Cyanotic, Dyspneic Elderly Man: Respiratory Failure
Respiratory failure is a condition in which the respiratory system fails to maintain adequate gas exchange, resulting in hypoxemia with or without hypercapnia, often presenting with cyanosis and dyspnea, particularly in elderly patients with compromised cardiopulmonary reserve.
Respiratory Failure: A Cyanotic, Dyspneic Elderly Man
The Big Idea: This lecture teaches you to recognise respiratory failure, understand why it happens from first principles (the four pathophysiological mechanisms), classify it (Type I vs Type II), assess its severity, interpret ABGs, deliver oxygen safely, and institute ventilatory support when needed. It is a core emergency medicine/respiratory topic that integrates physiology, clinical assessment, and acute management.
Learning Objectives (derived from lecture):
- Define and distinguish Type I and Type II respiratory failure
- Explain the four mechanisms of hypoxaemia
- Differentiate hypoxaemia from hypoxia
- Understand cellular consequences of hypoxia
- Recognise clinical signs of respiratory distress
- Interpret ABGs systematically
- Calculate and apply the A-a gradient
- Understand oxygen delivery devices, their pros/cons, and dangers of excessive O₂
- Understand indications for non-invasive positive pressure ventilation (NPPV)
Core Concepts and Mechanisms
Hypoxaemia is defined as an abnormally low level of oxygen in the blood (i.e., low partial oxygen tension). [1]
Hypoxia is defined as a condition where the oxygen supply is inadequate either to the body as a whole (generalised hypoxia) or to a specific region (tissue hypoxia). [1]
Why the distinction matters: You can have hypoxaemia without tissue hypoxia (mild desaturation with good cardiac output compensates), and you can have tissue hypoxia without hypoxaemia (e.g., carbon monoxide poisoning—PaO₂ is normal but O₂ delivery is impaired, or anaemia where Hb is low). Understanding this prevents you from falsely reassuring a patient with a "normal" PaO₂ who actually has impaired O₂ delivery.
| Feature | Type I (Hypoxaemic) | Type II (Hypercapnic) |
|---|---|---|
| PaO₂ | ≤ 8 kPa (60 mmHg) on room air [1] | Often low on room air, but may be normal after oxygen; hypoxaemia is not required in every definition |
| PaCO₂ | Normal or low | Elevated (≥ 6.0 kPa / about 45 mmHg) [11] |
| pH | Depends on the accompanying acid-base disorder | < 7.35 identifies acute respiratory acidaemia; a normal pH may reflect chronic renal compensation [11][12] |
| Primary problem | Oxygenation failure | Ventilation failure |
| Mechanism | V/Q mismatch, shunt, diffusion impairment | Hypoventilation, increased dead space |
| Typical causes | Pneumonia, PE, ARDS, ILD, acute pulmonary oedema | COPD exacerbation, drug overdose, neuromuscular disease, chest wall disease, obesity hypoventilation |
High Yield – Type I vs Type II
Type I RF: PaO₂ ≤ 8 kPa on room air with normal/low PaCO₂. Type II RF: elevated PaCO₂ from inadequate effective alveolar ventilation; hypoxaemia commonly coexists. The key discriminator is the PaCO₂. pH describes acuity, not the definition: pH < 7.35 means respiratory acidaemia, while chronic CO₂ retention may be compensated. [1][11][12]
Why does Type I RF have normal/low PaCO₂? In diseases causing V/Q mismatch or shunt, the patient compensates by hyperventilating. CO₂ is ~20× more diffusible than O₂ across the alveolar membrane, so hyperventilation effectively washes out CO₂ from well-ventilated regions even if those regions can't fully compensate for O₂. Hence PaCO₂ drops or stays normal, but PaO₂ remains low because O₂ diffusion is harder to compensate.
Why does Type II RF develop? When the ventilatory pump fails (CNS depression, neuromuscular weakness, chest wall disease, or severe airway obstruction), minute ventilation falls. Since alveolar ventilation is the only route for CO₂ elimination, CO₂ accumulates.
The CO₂ level in arterial blood is directly proportional to the rate of CO₂ production (VCO₂) and inversely proportional to the rate of CO₂ elimination by the lung (alveolar ventilation). Alveolar ventilation (VA) = VE × [1 − VD/VT]. Increased dead space and reduced minute ventilation are common causes of hypercapnia. [1]
3. The Four Mechanisms of Hypoxaemia
This is the physiological backbone of the lecture. Every cause of respiratory failure operates through one or more of these mechanisms.
Ventilation-perfusion (V/Q) mismatch refers to an imbalance of blood flow and ventilation. It causes the composition of alveolar gas to vary among lung regions: lung regions with low ventilation compared to perfusion will have a low alveolar oxygen content and high CO₂ content; lung regions with high ventilation compared to perfusion will have a low CO₂ content and high oxygen content. [1]
From first principles: Ideal gas exchange requires matched ventilation and perfusion (V/Q ≈ 1). If an area is perfused but poorly ventilated (low V/Q → e.g., mucus plugging, bronchospasm), blood leaving that region is poorly oxygenated. If an area is ventilated but poorly perfused (high V/Q → dead space, e.g., PE), gas exchange is wasted.
In the diseased lung, V/Q mismatch increases because heterogeneity of both ventilation and perfusion worsen. The net effect is hypoxaemia. Hypoxaemia due to V/Q mismatch can be corrected with low to moderate flow supplemental oxygen. [1]
Why does supplemental O₂ help? Increasing FiO₂ raises PAO₂ in all ventilated units, including those with low V/Q. The higher O₂ gradient drives more O₂ into blood even in poorly ventilated units.
Conditions causing V/Q mismatch: [1]
- Obstructive lung diseases (COPD, asthma)
- Pulmonary vascular diseases (PE)
- Interstitial lung diseases
- Low flow/impaired cardiac output states (reduce perfusion globally)
Physiological dead space: [1]
- Areas ventilated but not perfused; high V/Q
- Large saddle PE, severe obstructive lung disease
A right-to-left shunt exists when blood passes from the right to the left side of the heart without being oxygenated. [1]
Two types: [1]
- Anatomic shunts — alveoli are bypassed entirely: intracardiac shunts (e.g., Eisenmenger's), pulmonary AVMs, hepatopulmonary syndrome
- Physiologic shunts — non-ventilated alveoli are perfused: atelectasis, alveolar filling with blood/pus/cells/water/microbes (e.g., pneumonia, pulmonary oedema, ARDS)
Right-to-left shunts cause extreme V/Q mismatch, with a V/Q ratio of zero in some lung regions. The net effect is hypoxaemia, which is difficult to correct with supplemental oxygen. [1]
Exam Discriminator: V/Q Mismatch vs Shunt
V/Q mismatch responds to supplemental O₂. True shunt does NOT respond well to supplemental O₂. This is because in shunt, blood completely bypasses ventilated alveoli — no amount of extra O₂ in the alveolus can oxygenate blood that never reaches it. In V/Q mismatch, some ventilation still occurs, so raising FiO₂ helps. [1]
The Shunt Equation: [1]
Where:
- Qs/Qt = shunt fraction
- CcO₂ = end-capillary oxygen content (estimated from PAO₂)
- CaO₂ = arterial oxygen content
- CvO₂ = mixed venous oxygen content (~15 mL O₂/dL normally)
Oxygen content equation: [1]
The first term (bound to Hb) dominates. The dissolved component (0.0031 × PaO₂) is tiny. This is why anaemia causes tissue hypoxia even with normal PaO₂, and why giving 100% O₂ to a shunt patient barely improves CaO₂ — the shunted blood's Hb is still desaturated.
True mixed venous blood is sampled from the pulmonary artery after venous return from the SVC, IVC and coronary sinus has mixed. A right-atrial sample is central venous blood, not a fully mixed venous sample.
Diffusion limitation exists when the movement of oxygen from the alveolus to the pulmonary capillary is impaired. It is usually a consequence of alveolar and/or interstitial inflammation and fibrosis, such as that due to interstitial lung disease. In such diseases, diffusion limitation usually coexists with V/Q mismatch, which makes the relative contribution of each to the patient's hypoxemia uncertain. [1]
Why exercise worsens it:
During rest, blood traverses the lung relatively slowly. Thus, there is usually sufficient time for oxygenation to occur even if diffusion limitation exists. [1]
During exercise, cardiac output increases and blood traverses the lung more quickly. As a result, there is less time for oxygenation. In healthy individuals, compensatory mechanisms occur: pulmonary capillaries dilate (increasing surface area), and PAO₂ increases (increasing the O₂ gradient). In patients with diffusion limitation (such as with pulmonary fibrosis), there is insufficient time for oxygenation to occur. Most such patients have parenchymal destruction, rendering it impossible to recruit additional surface area. The net effect is measurable hypoxemia. [1]
Clinical pearl: Diffusion limitation is classically characterised by exercise-induced or exercise-exacerbated hypoxaemia [1]. At rest, PaO₂ may be normal. On exertion (e.g., 6-minute walk test), SpO₂ drops. This is a hallmark of ILD.
The lung alveolus is a space in which gas makes up 100% of the contents. Once the partial pressure of one gas rises, the other must decrease. Both arterial (PaCO₂) and alveolar (PACO₂) carbon dioxide tension increase during hypoventilation, which causes the alveolar oxygen tension (PAO₂) to decrease. As a result, diffusion of oxygen from the alveolus to the pulmonary capillary declines with a net effect of hypoxemia and hypercapnia. The PaCO₂ is elevated. [1]
From first principles: The alveolar gas equation (below) shows that PAO₂ depends on PaCO₂. If PaCO₂ rises (hypoventilation), PAO₂ must fall — there's only so much "space" for gas in the alveolus.
Causes of hypoventilation: [1]
| Category | Examples |
|---|---|
| CNS depression | Drug overdose, structural/ischaemic CNS lesions affecting respiratory centre |
| Obesity | Obesity hypoventilation syndrome |
| Impaired neural conduction | ALS, Guillain-Barré syndrome, high cervical spine injury, phrenic nerve paralysis, aminoglycoside blockade |
| Muscular weakness | Myasthenia gravis, idiopathic diaphragmatic paralysis, polymyositis, muscular dystrophy, severe hypothyroidism |
| Poor chest wall elasticity | Flail chest, kyphoscoliosis |
The image in the lecture is best read from the respiratory controller to the alveolus:
- “Won't breathe” — reduced central drive: sedatives/opioids, brainstem disease, sleep-related hypoventilation, severe hypothyroidism or hypothermia.
- “Can't breathe” — failure of nerve, neuromuscular junction, muscle or chest wall: spinal cord disease, GBS, myasthenia, motor-neuron disease, myopathy, diaphragm weakness, kyphoscoliosis or flail chest.
- “Can't breathe enough” — a large pulmonary load overwhelms ventilatory reserve: severe COPD/asthma with dynamic hyperinflation, severe pulmonary vascular disease/PE or end-stage ILD.
- Hypercapnia can also be worsened by increased CO₂ production (fever, sepsis/catabolism, thyrotoxicosis, overfeeding, metabolic acidosis or exercise) and severe upper-airway obstruction.
High Yield – Unique Feature of Hypoventilation
Pure hypoventilation has a normal A-a gradient. Low inspired oxygen (for example at altitude) can also cause hypoxaemia with a normal A-a gradient. V/Q mismatch, shunt and diffusion impairment widen the gradient; a mixed process can therefore widen the gradient even when hypoventilation is present. [1][2]
| Mechanism | PaO₂ | PaCO₂ | A-a Gradient | Response to Supplemental O₂ | Classic Example |
|---|---|---|---|---|---|
| V/Q Mismatch | ↓ | Normal/↓ | Widened | Responds well | COPD, PE, asthma |
| Shunt | ↓ | Normal/↓ | Widened | Poor response | Pneumonia, ARDS, atelectasis |
| Diffusion Limitation | ↓ (especially on exertion) | Normal/↓ | Widened | Responds | ILD, pulmonary fibrosis |
| Hypoventilation | ↓ | ↑ | Normal | Responds | Drug OD, GBS, OHS |
Cellular hypoxia is a state in which there is insufficient oxygen to meet the metabolic demands of a given tissue. [1]
Cellular tolerance of hypoxia is variable. The slide's “four to six minutes” should be read as an emergency teaching approximation for complete cerebral circulatory arrest, not a universal timer for every degree of hypoxaemia; injury depends on severity, duration, perfusion, temperature and metabolic demand. [1]
Cellular mechanisms of hypoxic injury: [1]
- Depletion of ATP — aerobic metabolism fails, ATP production drops, ion pumps fail
- Intracellular acidosis — anaerobic glycolysis produces lactate
- Increased metabolic by-products — oxygen free radicals, destruction of membrane phospholipids
- Increased intracellular calcium — damages cytoskeleton, induces apoptosis-related genes
- Inflammatory reaction — neutrophilic infiltration, cytokine release, free radicals, microcirculation disruption
Clinical significance: Severe hypoxaemia and inadequate oxygen delivery require urgent correction, but airway and ventilation decisions should follow the patient's physiology and trajectory rather than a rigid minute threshold.
Clinical Assessment of Respiratory Failure
Respiratory distress signs: [1]
- Tachypnoea, commonly respiratory rate > 20/min in adults (usual resting reference range about 12–20/min)
- Tachycardia
- Cyanosis
- Use of accessory muscles (neck, intercostal in-sucking), gasping
- Drowsiness (hypoxia, acute CO₂ retention)
- Bradycardia, cardiac arrest (late, ominous)
Minor hypoxemia may cause few symptoms or signs. More substantial desaturation can be accompanied by increased respiratory drive (therefore tachypnea and breathlessness), increased sympathetic tone, anxiety, restlessness and sweating. Hypoxemia produces arterial vasodilation and venous constriction (related to increased sympathetic tone). [1]
Mild to moderate/develops slowly: Anxious, mild dyspnea, daytime sluggishness, headaches, or hypersomnolence. [1]
Higher levels of CO₂ or rapidly developing: Frank alterations in sensorium including delirium, paranoia, depression, and confusion, which progress to somnolence and then coma (CO₂ narcosis) as levels continue to rise. [1]
Severe: Asterixis, myoclonus, and seizures as well as papilledema, and dilated superficial veins. [1]
| Severity | Symptoms/Signs |
|---|---|
| Mild/Chronic | Headache, daytime somnolence, anxiety |
| Moderate/Acute | Delirium, confusion, paranoia → somnolence → CO₂ narcosis (coma) |
| Severe | Asterixis (flapping tremor), myoclonus, seizures, papilloedema, dilated superficial veins |
Exam Discriminator: Hypoxia vs Hypercapnia Symptoms
For the 2024 MCQ, headache is the best discriminator because it suggests hypercapnia: CO₂-mediated cerebral vasodilatation can cause headache, flushing, a bounding pulse and, when severe, papilloedema. Clinically, however, headache is not exclusive to Type II failure and its absence does not exclude hypercapnia. [1][4]
From the lecture slides: [1]
- Mental status — confusion (hypoxia), drowsiness (CO₂ retention)
- Heart rate — tachycardia (sympathetic drive); bradycardia (late/ominous)
- Respiratory rate — tachypnoea
- Respiratory pattern:
- Rapid shallow respiratory efforts, sternal retraction, use of accessory muscles
- Thoracoabdominal paradoxical movement — diaphragm moves cranially, abdomen moves inward with inspiration = fatiguing diaphragm working against a fatiguing load
- Respiratory alternans — breathing alternates between predominantly abdominal and predominantly rib cage movements = sign of increased load
- Inspection of skin, lips, tongue, nail beds — cyanosis
- Pulmonary and cardiac auscultation
- Blood pressure, ECG
- Search for signs of cor pulmonale: peripheral oedema, dilated jugular veins, hepato-jugular sign [1]
Investigations
Assess airway, breathing, circulation → ABG → ± A-a gradient → CXR → ± CT thorax/CT brain → Administer oxygen → ± Ventilatory support → Treat the underlying cause. [1]
Arterial blood gases: Blood taken from artery. Send to the lab in ice as soon as possible. No excessive heparin. [1]
Specimen-Handling Update
Treat the slide's “send on ice” line as historical shorthand, not a universal rule for modern plastic blood-gas syringes. Expel air bubbles, cap and gently mix the correctly filled, dry-balanced-heparin syringe, record the inspired oxygen/device, and analyse or transport it immediately according to the local laboratory protocol. Cooling a plastic syringe can itself alter PaO₂; use ice only when the local laboratory specifies it for a delayed/special sample. Air bubbles tend to move PaO₂ toward the ambient value and lower PaCO₂, while excess liquid heparin dilutes the sample. [14][16]
From the lecture [1]:
Step 1: pH
- Acidaemic: pH < 7.35
- Normal: 7.35–7.45
- Alkalaemic: > 7.45
Step 2: pCO₂ (Normal: 4–6 kPa)
- If elevated with acidaemia → respiratory acidosis
Step 3: HCO₃⁻ (Normal: 21–27 mEq/L)
- Metabolic status
- Renal compensation, chronicity
Expanded approach (from supporting notes): [2]
- Oxygenation: PaO₂ and A-a gradient
- Acid-base: pH
- Primary disorder: PaCO₂ (respiratory) vs HCO₃⁻ (metabolic)
- Compensation: expected compensation ranges
- Anion gap (if metabolic acidosis)
The alveolar to arterial (A-a) oxygen gradient is the difference between alveolar oxygen tension (PAO₂) and arterial oxygen tension (PaO₂). [1]
A-a gradient = PAO₂ − PaO₂ [1]
PAO₂ = (FiO₂ × [Patm − PH₂O]) − (PaCO₂ ÷ R) [1]
Where:
- FiO₂ = 0.21 at room air
- Patm = 760 mmHg at sea level
- PH₂O = 47 mmHg at 37°C
- R = respiratory quotient = 0.8 at steady state
Normal A-a gradient = 2.5 + 0.21 × age in years [1]
Why it matters: A widened A-a gradient tells you the problem is in the lungs (V/Q mismatch, shunt, or diffusion impairment). A normal A-a gradient with hypoxaemia and hypercapnia points to hypoventilation (the lungs themselves are fine — the pump is failing).
A sensor is placed at a perfused thin part of the body (e.g., fingertip, earlobe). Detects pulse rate (important in determining signal quality). Emits 2 wavelengths (660 nm red, 940 nm infrared), determines absorbances due to pulsing arterial blood alone, excluding venous blood, skin, bone, muscle, and fat. [1]
Limitations of pulse oximetry (important for exams):
- Inaccurate in poor perfusion (shock, hypothermia, Raynaud's)
- Cannot detect CO poisoning (carboxyhaemoglobin absorbs similarly to oxyhaemoglobin at 660 nm → falsely high SpO₂)
- Cannot detect methaemoglobinaemia (reads ~85% regardless)
- Inaccurate with nail polish, excess ambient light
- Lags behind real-time changes (30-60 second delay)
- Does NOT measure PaCO₂ — a patient can have normal SpO₂ but be retaining CO₂
Reading the Plethysmography Diagram
The two repeated image slides are teaching signal validation, not just the saturation number:
| Pleth trace | Visual appearance | Interpretation/action |
|---|---|---|
| Normal signal | Regular pulsatile waveform matching the palpated/ECG pulse | SpO₂ is more likely to be trustworthy |
| Low perfusion | Very low-amplitude, nearly flat waveform | Warm/reposition the limb, improve perfusion or try an ear/forehead sensor |
| Electrical/optical noise | Fine irregular high-frequency oscillation | Remove ambient/electrical interference and re-site the probe |
| Motion artefact | Large chaotic deflections that do not match the true pulse | Keep the patient/probe still and confirm the displayed pulse rate independently |
Never accept an isolated SpO₂ value without a plausible pleth waveform and pulse rate. If the reading conflicts with the patient, repeat it and obtain an ABG with co-oximetry when dyshemoglobinaemia is possible.
Arterial oxygen saturation (SpO₂ and SaO₂) [1]
SpO₂ is a non-invasive estimate. SaO₂ may be calculated by some blood-gas analysers or directly measured by co-oximetry; the distinction matters in carbon monoxide poisoning and methaemoglobinaemia.
The oxygen-haemoglobin dissociation curve — sigmoid shape means:
- At high PaO₂ (> 8 kPa), Hb is nearly fully saturated → SpO₂ changes little
- At PaO₂ around 8 kPa (60 mmHg), you're on the steep part of the curve → small drops in PaO₂ cause large drops in SpO₂
- This is why PaO₂ ≤ 8 kPa is the threshold for respiratory failure — below this, O₂ delivery deteriorates rapidly
Oxygen Therapy
Room air contains about 21% oxygen (FiO₂ 21%). [1]
For low-flow devices, delivered FiO₂ varies with respiratory rate, inspiratory flow and air entrainment. [1]
Prescribe a target saturation range plus the device and starting flow/FiO₂, then titrate and reassess. Oxygen is a treatment for hypoxaemia, not breathlessness alone. [11]
| Device | FiO₂ Range | Key Features |
|---|---|---|
| Nasal cannula | ~24–44% (1–6 L/min) | Convenient, less disfiguring, allows feeding/expectoration |
| Venturi mask | Precise FiO₂ (24–60%) | Colour-coded adaptors, controlled O₂ — ideal for COPD |
| Reservoir/non-rebreathing mask | High, variable FiO₂ (commonly 10–15 L/min; 15 L/min in critical illness) | Reservoir bag and valves; keep the bag inflated and obtain urgent definitive assessment [11] |
Nasal Cannula — Pros and Cons [1]
Pros: Convenient, less disfigurement. Easy to feed, allow expectoration of sputum.
Cons: FiO₂ not exact. High flow O₂ (i.e., > 6 L/min) not recommended, due to discomfort, drying of nasal passage and epistaxis (humidification needed). Dislodgement.
Dangers of oxygen: [1]
- Carbon dioxide retention, especially in COPD (excessive oxygen knocks off the hypoxic respiratory drive)
- Lung toxicity, exacerbate lung injury
- Oxidative stress and cell injury
- Resorption atelectasis
High Yield – Why Does O₂ Cause CO₂ Retention in COPD?
The slide uses the traditional “loss of hypoxic drive” explanation, but that is not the principal mechanism in most acute COPD exacerbations. Excess oxygen mainly reverses hypoxic pulmonary vasoconstriction, worsening V/Q mismatch, and causes the Haldane effect (oxygenated Hb carries less CO₂); a fall in minute ventilation may contribute. The practical lesson remains: never withhold oxygen from a hypoxaemic patient, but titrate controlled oxygen—commonly to SpO₂ 88–92% while awaiting/repeating the ABG in someone at risk of hypercapnic respiratory failure. [1][2][5]
The diagram maps high inspired oxygen pressure, especially when prolonged or hyperbaric, to several injury pathways:
| Site | Diagrammed consequence |
|---|---|
| Tracheobronchial tree, capillary endothelium and alveolar epithelium | Chemical injury → pulmonary damage, absorption atelectasis, worsening hypoxaemia and acidosis |
| Retina | Retinal injury (particularly relevant to premature infants and hyperbaric exposure) |
| CNS | Enzyme/cellular toxicity → twitching or convulsions at sufficiently high exposure |
| Other tissues | The slide also labels erythrocyte, myocardial, renal, hepatic and endocrine effects |
These are dose- and duration-dependent toxicities, not reasons to delay oxygen in life-threatening hypoxaemia.
Resorption atelectasis explained: When breathing high FiO₂, nitrogen (normally 78% of alveolar gas) is washed out and replaced by O₂. If an airway becomes partially obstructed, the O₂ in the trapped alveolus is rapidly absorbed into blood (O₂ is much more soluble than N₂). Without N₂ to "splint" the alveolus open, it collapses.
Non-Invasive Positive Pressure Ventilation (NPPV)
Strong evidence (multiple controlled trials):
- COPD
- Acute cardiogenic pulmonary oedema
- Immunocompromised patients with diffuse lung infiltrates
Less strong evidence (single controlled trial or multiple case series):
- Pneumonia
- Asthma
- Postoperative respiratory failure
- Avoidance of extubation failure
- "Do not intubate" patients
Weak evidence (few case series or case reports):
- Upper airway obstruction
- Acute respiratory distress syndrome
- Trauma
The quoted hierarchy is the lecture's historical evidence summary, not a timeless ordering. The official ERS/ATS guideline gives strong recommendations for bilevel NIV in COPD exacerbation with acute respiratory acidosis and for CPAP or bilevel NIV in acute cardiogenic pulmonary oedema. It gives conditional recommendations in selected immunocompromised, postoperative, palliative, trauma and high-risk post-extubation settings; it makes no recommendation for acute asthma or de-novo hypoxaemic failure and recommends against NIV as treatment for established post-extubation respiratory failure. Patient selection, monitoring and rapid escalation matter as much as the label. [13]
NPPV is also indicated as long-term ventilatory support for patients suffering from chronic respiratory failure secondary to restrictive lung disease due to neuromuscular or chest wall disease, sleep-related breathing disorders and COPD. [1]
Why NPPV works in COPD exacerbation: NPPV (typically bilevel — IPAP/EPAP or BiPAP) provides inspiratory pressure support to augment tidal volume (overcoming increased airway resistance and respiratory muscle fatigue) and expiratory positive pressure to counteract auto-PEEP (intrinsic PEEP from air trapping). This improves alveolar ventilation → PaCO₂ decreases → pH improves → avoids intubation.
Why NPPV in cardiogenic pulmonary oedema: Positive pressure reduces venous return (preload) and afterload on the LV → reduces pulmonary oedema. Also recruits flooded alveoli and reduces shunt.
The slide combines clinical work of breathing with gas-exchange failure. For acute COPD exacerbation, the BTS/ICS threshold is more specific: after about one hour of optimal medical treatment and controlled oxygen, start NIV when pH < 7.35, PaCO₂ ≥6.5 kPa and RR > 23/min persist or develop; consider NIV at PaCO₂ 6.0–6.5 kPa according to the whole picture. [12]
- increasing dyspnoea of at least moderate severity
- respiratory rate > 24/min, accessory-muscle use or respiratory paradox
- respiratory acidaemia (pH < 7.35) with hypercapnia
- severe oxygenation impairment (PaO₂/FiO₂ < 200) as an additional warning feature
Printed Sign Error on the Slide
The slide visibly prints PaCO₂ < 45 mmHg under indications for NIPPV in type II respiratory failure. That inequality is physiologically inconsistent: type II failure is hypercapnic, so the intended direction is PaCO₂ above the reference range, together with respiratory acidaemia. For AECOPD, use the guideline threshold above rather than memorising the slide's generic cut-off. [12]
The contraindication image is fundamentally an airway-safety and immediate-stability checklist:
| Problem | Why NIV may be unsafe or inadequate |
|---|---|
| Cardiac or respiratory arrest; severe haemodynamic/electrical instability | Requires immediate resuscitation and a definitive airway |
| Inability to protect the airway, high aspiration risk, vomiting/ileus or major GI bleeding | The mask does not protect against aspiration |
| Severe encephalopathy or an uncooperative patient | Cannot reliably tolerate the mask or manage secretions; hypercapnic obtundation may still improve in a closely monitored expert setting |
| Severe bulbar dysfunction or inability to clear secretions | Poor airway protection and secretion retention |
| Fixed upper-airway obstruction | Positive pressure cannot bypass the obstruction |
| Facial/nasopharyngeal trauma, deformity or recent upper-airway surgery | A safe seal may be impossible; local injury may be worsened |
| Recent upper-GI surgery | Usually a relative contraindication requiring specialist judgement |
The slide also lists acute coronary syndrome. In practice this is not a stand-alone universal prohibition; decide according to haemodynamic stability, pulmonary oedema, ischaemia and the ability to monitor/escalate. NIV must never delay intubation when it is failing.
From the 2023 minicase Q13 (asking for two types of ventilatory support) [3]:
- Non-invasive positive pressure ventilation (NPPV / NIPPV / BiPAP / CPAP)
- Invasive mechanical ventilation (endotracheal intubation + ventilator)
Reading the Interface and Circuit Visuals
- The non-invasive photographs show a total-face/helmet-style interface and an oronasal mask. Success depends on fit and synchrony: minimise leak, protect the nasal bridge/skin, coach the patient, and reassess comfort, respiratory rate, mental status and ABG early.
- CPAP supplies one continuous pressure and principally recruits alveoli/improves oxygenation. Bilevel NIV adds inspiratory pressure support above EPAP/PEEP, increasing tidal volume and CO₂ clearance—hence its role in acute hypercapnic COPD.
- The invasive-ventilation diagram shows a cuffed endotracheal tube bypassing the upper airway, with inspiratory and expiratory limbs, filter, heated humidifier and monitoring/control interface. The adjacent nasogastric tube enters the stomach; it is not part of the airway circuit.
- Invasive ventilation protects the airway and allows controlled ventilation but requires sedation/airway expertise and carries ventilator-associated and lung-injury risks. NIV is not a lesser version of intubation when airway protection or immediate invasive support is required.
The chronic-management slide presents a ladder rather than oxygen alone:
- treat the underlying disease and remove aggravating factors
- pulmonary rehabilitation
- long-term oxygen therapy (LTOT/HOT) when chronic resting hypoxaemia meets criteria
- domiciliary ventilation, non-invasive or invasive, for selected chronic ventilatory failure
- selected emphysema: lung-volume-reduction intervention
- selected advanced disease: lung transplantation
Lecture criteria for home oxygen in stable COPD:
| Resting measurement | Additional requirement |
|---|---|
| PaO₂ < 55 mmHg (about 7.3 kPa), or SaO₂ < 89% | None on the slide |
| PaO₂ 55–59 mmHg (about 7.3–7.9 kPa), or SaO₂ about 89% | Cor pulmonale or secondary polycythaemia (slide: haematocrit > 56%) |
Assess this in a stable, optimally treated patient rather than from a transient value during an acute exacerbation, and use the applicable local oxygen-service protocol.
Approach to Specific Clinical Scenarios
This is the most commonly tested scenario integrating this lecture's content:
- Recognise respiratory failure: tachypnoea, accessory muscle use, cyanosis, drowsiness
- ABG: Type II RF is defined by ↑PaCO₂; pH < 7.35 identifies acute respiratory acidaemia and elevated HCO₃⁻ suggests chronic compensation
- Controlled O₂: 1-2 L/min nasal cannula or 24-28% Venturi mask → target SpO₂ 88-92%
- Optimal medical treatment + repeat ABG within about 30–60 minutes
- NIV (usually bilevel): if pH < 7.35, PaCO₂ ≥6.5 kPa and RR > 23/min persist/develop after about one hour; do not delay if clinical deterioration demands earlier expert escalation [11][12]
- If NIPPV fails → invasive mechanical ventilation
- Treat underlying cause: bronchodilators (salbutamol + ipratropium nebulised), systemic corticosteroids, antibiotics if infective exacerbation [5]
| Parameter | Result | Normal |
|---|---|---|
| pH | 7.28 | 7.35–7.45 |
| PaO₂ | 8.0 kPa | 10.6–14.0 |
| PaCO₂ | 7.0 kPa | 4.7–6.0 |
| HCO₃⁻ | 35 mmol/L | 22–26 |
| Base excess | −6 | −4 to +2 |
Interpretation:
- pH 7.28 indicates acidaemia, PaCO₂ 7.0 kPa is elevated and PaO₂ 8.0 kPa is at the lecture's hypoxaemic-failure cutoff.
- However, the printed set is internally inconsistent: HCO₃⁻ 35 mmol/L and PaCO₂ 7.0 kPa would not produce pH 7.28, and a base excess of −6 conflicts with HCO₃⁻ 35.
- Therefore, do not force a precise mixed-disorder or chronicity diagnosis from these copied values. Recheck the original report/question and interpret the internally consistent result. If the intended data show acidaemia + raised PaCO₂ + raised HCO₃⁻, that would support acute-on-chronic hypercapnic respiratory failure.
Integration with Related Material
From Felix Lai's notes [6] and GC 147 [7]:
| Type | Mechanism | Examples |
|---|---|---|
| Central cyanosis | Systemic arterial desaturation/dysfunctional haemoglobin; inspect tongue and oral mucosa as well as skin | Respiratory failure, cyanotic CHD, pneumonia; a large PE may cause it when hypoxaemia is severe |
| Peripheral cyanosis | Increased O₂ extraction / slow capillary flow | Cold exposure, shock, DVT, Raynaud's |
| Differential cyanosis | Upper and lower extremities have different saturations | Classically lower-limb cyanosis with a right-to-left shunt through a PDA distal to the left subclavian artery |
Do not use colour as an oximeter. The traditional teaching threshold is about 5 g/dL of deoxygenated Hb, but visual recognition varies with lighting, pigmentation, perfusion and observer. Anaemia can mask cyanosis despite dangerous hypoxaemia, whereas polycythaemia can make it more apparent at a higher saturation.
This is a historical paediatric screening concept, not a substitute for urgent pulse oximetry, blood gas/co-oximetry and echocardiography [8]:
- Give 100% O₂ for 10 minutes
- Lung disease: PaO₂ usually exceeds 15 kPa (lungs can be recruited)
- Cyanotic CHD: PaO₂ remains relatively unchanged (blood bypasses lungs via shunt)
Do not delay definitive assessment in a critically ill infant to perform it, and interpret any response as a continuum rather than an absolute diagnostic split.
All of:
- Acute onset (≤ 7 days)
- Bilateral CXR/CT opacities not fully explained by effusions, lobar/lung collapse or nodules
- Respiratory failure not fully explained by cardiac failure or fluid overload; use objective assessment such as echocardiography if no ARDS risk factor is apparent (Berlin removed the PCWP < 18 mmHg requirement) [15]
- With PEEP/CPAP ≥5 cmH₂O: mild 200 <PaO₂/FiO₂ ≤300, moderate 100 <PaO₂/FiO₂ ≤200, severe ≤100 mmHg [15]
Chronic hypoxia → pulmonary vasoconstriction → pulmonary hypertension → right heart failure. Signs: peripheral oedema, raised JVP, hepatomegaly, hepato-jugular reflux. ECG: P pulmonale, right axis deviation, RVH.
| Trap | Correct Answer |
|---|---|
| Assuming all hypoxaemic patients need unregulated high-flow O₂ | Give enough oxygen for the clinical urgency, then titrate: usually 94–98%, or 88–92% pending ABG when hypercapnic failure is a risk [11] |
| Confusing hypoxaemia with hypoxia | Hypoxaemia = low blood O₂; Hypoxia = inadequate tissue O₂ |
| Thinking normal SpO₂ excludes respiratory failure | SpO₂ doesn't measure CO₂ — Type II RF can have normal SpO₂ |
| Forgetting A-a gradient is normal in pure hypoventilation | If A-a gradient is normal + hypercapnia → pump failure, not lung disease |
| Treating the lecture's old NIV evidence ladder as universal | Strongest guideline support: acidotic AECOPD and cardiogenic pulmonary oedema; other uses are conditional or unsupported and need careful selection [13] |
| Using SpO₂ to diagnose CO poisoning | SpO₂ is falsely normal in CO poisoning — need co-oximetry |
| Mistaking chronic for acute respiratory acidosis | High HCO₃⁻ = renal compensation = chronicity |
High Yield Summary
-
Respiratory failure = failure of gas exchange defined by ABG
- Type I: PaO₂ ≤ 8 kPa, normal/low PaCO₂ → oxygenation failure → V/Q mismatch (most common), shunt (refractory to O₂), diffusion impairment
- Type II: elevated PaCO₂ from inadequate effective alveolar ventilation; hypoxaemia often coexists. pH < 7.35 marks acute respiratory acidaemia, not the definition.
-
Four mechanisms of hypoxaemia
- V/Q mismatch (responds to O₂), shunt (doesn't respond), diffusion limitation (exercise-induced), hypoventilation (normal A-a gradient, elevated PaCO₂)
-
ABG approach
- pH → PaCO₂ → HCO₃⁻ → A-a gradient → PaO₂/FiO₂ ratio
-
Oxygen therapy
- Nasal cannula (convenient, imprecise FiO₂), Venturi mask (precise, for COPD), non-rebreathing mask (high FiO₂). Dangers: CO₂ retention in COPD, lung toxicity, resorption atelectasis.
-
NPPV
- Strongest acute guideline support for acidotic COPD exacerbation and acute cardiogenic pulmonary oedema; other settings need indication-specific selection. Also used chronically in selected neuromuscular/chest-wall disease and hypercapnic COPD.
-
Target SpO₂
- General > 94%; COPD 88-92%.
-
Signs of respiratory failure for exams
- Tachypnoea, tachycardia, cyanosis, accessory muscle use, drowsiness, paradoxical abdominal movement, respiratory alternans, cor pulmonale signs.
Active Recall - Respiratory Failure
[1] Lecture slides: GC 023. A cyanotic, dyspneic elderly man_respiratory failure.pdf (all pages) [2] Senior notes: Maksim Medicine Notes.pdf (Respiratory medicine section, pp. 284-302) [3] Past papers: 2023 Fourth Summative Minicase.pdf (Case One, Q10-13) [4] Past papers: 2024 Fourth Summative MCQ.pdf (Q24, EMQ Q1-4) [5] Senior notes: Ryan Ho Respiratory.pdf (Section 2.5 Respiratory Failure) [6] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p. 603-605) [7] Lecture slides: GC 147. Heart failure and cyanosis in children acyanotic and cyanotic congenital heart disease - Part 2.pdf (p. 40) [8] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 279) [11] British Thoracic Society: Guideline for oxygen use in adults in healthcare and emergency settings [12] British Thoracic Society/Intensive Care Society: Guideline for the ventilatory management of acute hypercapnic respiratory failure in adults, including the 2017 PaCO₂-threshold correction [13] ERS/ATS: Official clinical practice guideline on non-invasive ventilation for acute respiratory failure [14] WHO: Guidelines on drawing blood—arterial blood sampling and immediate specimen transport [15] ARDS Definition Task Force: The Berlin Definition of ARDS [16] Australian and New Zealand Society of Respiratory Science: Position statement for arterial blood-gas sampling
GC022 Visual Spot Diagnoses - Survival Guide For Primary Care
A clinical reference covering key dermatological and physical examination findings that can be rapidly identified on sight to aid diagnosis and management in the primary care setting.
GC024 A Fatigued And Sleepy Patient
A clinical presentation in which persistent fatigue and excessive sleepiness suggest underlying conditions such as obstructive sleep apnea, hypothyroidism, anemia, or other systemic disorders requiring systematic evaluation.